Valuation: Biodesix, Inc.

Market Cap 230M 205M 188M 171M 321M 21.76B 327M 2.25B 906M 11.48B 862M 844M 36.27B P/E 2026 *
-8.15x
P/E 2027 * -13.1x
Enterprise Value 230M 205M 188M 171M 321M 21.76B 327M 2.25B 906M 11.48B 862M 844M 36.27B EV / Sales 2026 *
2.06x
EV / Sales 2027 * 1.71x
Free-Float
54.99%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week-1.73%
Current month-7.25%
1 month-25.77%
3 months-2.09%
6 months+91.39%
Current year+217.21%
1 week 21.27
Extreme 21.27
25.06
1 month 20.11
Extreme 20.11
30
Current year 5.26
Extreme 5.26
31.97
1 year 5.26
Extreme 5.26
31.97
3 years 3.44
Extreme 3.436
44.2
5 years 3.44
Extreme 3.436
166.87
10 years 3.44
Extreme 3.436
639.8
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2020
Director of Finance/CFO 46 01/04/2017
Chief Tech/Sci/R&D Officer - 01/01/2016
Director TitleAgeSince
Chairman 79 14/09/2020
Director/Board Member 53 01/01/2012
Director/Board Member 59 01/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Exercice

Chairman

2,720 0.0340%
8/12/26 A Buy 15,000 0.1422%
8/11/26 A Buy 13,700 0.1298%
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%-1.73%+240.22%-32.59% 230M
+0.90%-2.15%+13.68%+26.93% 113B
+0.06%+4.29%+1.67%+103.29% 97.71B
+2.57%-4.86%+97.17%+814.51% 54.62B
+3.88%+1.17%-6.04%+82.74% 30.65B
+0.37%+8.03%+38.75%+70.18% 28.87B
-0.20%+3.62%+40.54%+87.69% 27.59B
+1.78%+4.48%+35.95%+398.51% 21.4B
-1.28%-5.43%-21.72%-16.73% 19.74B
-1.15%-1.02%-5.94%+29.77% 17.04B
Average +0.57%-0.02%+43.43%+156.43% 41.1B
Weighted average by Cap. +0.90%-1.27%+22.79%+178.34%

Financials

2026 *2027 *
Net sales 112M 99.83M 91.61M 83.33M 156M 10.59B 159M 1.09B 441M 5.59B 420M 411M 17.65B 135M 120M 110M 100M 188M 12.75B 192M 1.32B 531M 6.73B 505M 495M 21.25B
Net income -27.51M -24.56M -22.54M -20.5M -38.44M -2.6B -39.21M -269M -109M -1.37B -103M -101M -4.34B -19.47M -17.39M -15.95M -14.51M -27.21M -1.84B -27.75M -191M -76.81M -973M -73.08M -71.53M -3.07B
Net Debt - -
Projected Income Statement - Annual - Biodesix, Inc.
Logo Biodesix, Inc.
Biodesix, Inc. is a diagnostic solutions company. The Company's business includes Biodesix Lung Diagnostic Testing and Biodesix Development Services. Its Biodesix Lung Diagnostic Testing provides lung diagnostic testing services for healthcare providers through five blood-based tests. Its Biodesix Development Services supports global biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that enable the development of diagnostic tests, tools, and therapeutics. The Company offers Nodify Lung tests and IQLung tests that assess cancer risk and provide treatment guidance following a lung cancer diagnosis. The Nodify Lung tests include Nodify CDT and Nodify XL2 tests, which evaluate the risk of lung cancer in lung nodules. The GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests are used in the diagnosis of lung cancer to detect tumor mutations and assess the patient’s immune system status.
Employees
334
Date Price Change Volume
03/11/26 $21.20 -2.66% 11,439
02/11/26 $21.78 -6.34% 75,630
30/10/26 $23.26 -5.93% 67,248
29/10/26 $24.72 +8.14% 70,235
28/10/26 $22.86 +4.15% 101,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Biodesix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
21.78USD
Average target price
39.00USD
Spread / Average Target
+79.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Biodesix, Inc.
  1. Stock Market
  2. Stocks
  3. BDSX Stock